Phase 2 N=82 A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis
Lupus Arthritis
Primary: Number of Participants With Adverse Events (AEs) — 21; 29; 25 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=66 Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches
Systemic Lupus Erythematosus
Primary: British Isles Lupus Assessment Group Index-based Combined Lupus Assessment (BICLA) — 8; 8 Participants — p=>0.999
N/A N=58 Exercise and Arterial Stiffness in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Arterial Stiffness — -0.26; -0.22 m/s
Phase 2 N=27 Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis
Systemic Lupus Erythematosus · Arthritis
Primary: Arthritis Complete Response — 4; 0 participants
Phase 4 N=38 Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease
Systemic Lupus Erythematosus (SLE)
Primary: Number of Participants Who Meet the Definition of a Responder Within 4 Weeks — 3; 4 Participants
Phase 2 N=102 A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
Lupus Erythematosus, Systemic
Primary: Percentage of Participants With a Systemic Lupus Erythematosus Responder Index (SRI-4) Composite Response (CR) at Week 24 — 33.3; 61.7 Percentage of participants…
Phase 4 N=87 Efficacy of Fish Oil in Lupus Patients
Systemic Lupus Erythematosus
Primary: Effect on Brachial Artery Flow Dilation by Omega-3 Versus Placebo. — 0.32; 0.33; 0.32; 0.33 cm — p=0.87
Phase 2 N=183 Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone
Systemic Lupus Erythematosus
Primary: Double Blind Period (DB); Number of Participants Experiencing a New SLE Flare — 94; 47 Participants
Phase 2 N=109 JBT-101 in Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus · SLE · Lupus
Primary: Improvement in the Maximum Daily NRS-Pain Score at Day 84 — 6.3; 6.4; 6.0; 6.2 NRS Pain Score — p=0.4190
Phase 2 N=25 A Study of DS-7011a in Patients With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Number of Participants With Treatment-emergent Adverse Events Following Administration With DS-7011a in Participants With Systemic Lupus Erythematosus — 11; 4 Participants
N/A N=699 Women Empowered to Live With Lupus Study
Lupus Erythematosus, Systemic
Primary: Communication With Physician - Stanford 3Q Scale Score — 3.1; 2.9; 3.3; 3.0 score on a scale
Phase 1 N=73 Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis
Systemic Lupus Erythematosus · Rheumatoid Arthritis
Primary: Number of Participants With Dose-Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Phase 2 N=76 ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Safety and Tolerability as Assessed by Number of Participants With Treatment- Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 23; 24; 2; 2 Participants
N/A N=34 Inflammation and Insulin Resistance in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Disease Activity Score Based on 28-joint Disease Activity Score (DAS28) — 4.40; 4.03; 4.57; 4.48 units on a scale
Phase 4 N=172 Acthar Gel for Active Systemic Lupus Erythematosus (SLE)
Lupus Erythematosus, Systemic
Primary: Physician's Global Assessment (PGA) — 58.8; 60.6; 33.2; 30.2 score on a scale
Phase 2 N=80 Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)
Systemic Lupus Erythematosus
Primary: Change in Vascular Function and Cardiometabolic Risk as Measured by Left CAVI at Month 3 — -0.32; 0.09 unitless
Phase 2 N=93 Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
Systemic Lupus Erythematosus
Primary: Percentage of Participants With SLE Responder Index (SRI) Response at Week 52 — 43.6; 52.8 Percentage of participants
Phase 1 N=32 A Study in Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 0; 0 participants
Phase 2 N=314 A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Primary: Percentage of Participants Who Achieve Remission of Arthritis and/or Rash Defined by the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) — 53.3…
Phase 2 N=185 A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State
Systemic Lupus Erythematosus (SLE)
Primary: Number of Participants With Treatment-Emergent Adverse Events — 34; 31; 30; 11 participants
N/A N=79 Living Well With Rheumatoid Arthritis
Rheumatoid Arthritis
Primary: RADAI Disease Activity Score — -0.4; 0.1 units on a scale — p=0.04
Phase 3 N=1,164 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus · Connective Tissue Disease · Autoimmune Disease
Primary: Percentage of Participants Achieving an SLE Responder Index Response at Week 52 — 31.8; 35.2; 29.3 percentage of participants
Phase 2 N=99 Prospective Study of Rapamycin for the Treatment of SLE
Systemic Lupus Erythematosus (SLE)
Primary: Reduction of the Disease Activity as Measured by SLEDAI and BILAG Scores. — 10.2; 28.4 score on a scale
Phase 2 N=350 A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
Systemic Lupus Erythematosus
Primary: Percentage of Participants Achieving SLE Responder Index (SRI) Change of 4 (SRI-4) at Week 52 — 64.6; 57.4; 69.7; 66.3 Percentage of participants — p=0.8076
Phase 3 N=1,004 A Rheumatoid Arthritis Study in Participants
Rheumatoid Arthritis
Primary: Percentage of Participants With American College of Rheumatology 20% (ACR20) Response — 34.4; 33.5; 31.5 percentage of participants
Phase 3 N=1,124 A Study of LY2127399 in Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus · Connective Tissue Disease · Autoimmune Disease
Primary: Percentage of Participants Achieving an SLE Responder Index Response at Week 52 — 38.5; 34.8; 27.7 percentage of participants
N/A N=178 Role of Oral and Intestinal Microbiota in Rheumatoid Arthritis (RA)
Rheumatoid Arthritis · Psoriatic Arthritis · Periodontal Disease
Primary: Alteration of Microbiota, Alteration of T Cell Function/Activation — 4; 10; 2; 0 participants
N/A N=6 Low-dose UVA1 Radiation in Cutaneous Lupus Patients
Cutaneous Lupus Erythematosus
Primary: Change in Cutaneous Lupus Disease Area and Severity Index (CLASI) Activity Score — -1 Units on a scale
Phase 2 N=119 Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis
Autoimmune Disorder · Rheumatoid Arthritis · Systemic Lupus Erythematosus
Primary: The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE — 60.0; 33.3 Percentage of participants…
Phase 2 N=158 Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus
Primary: Time to Flare Comparing Patients With Moderate vs Severe Disease Activity at Baseline — 45; 71 days to flare — p=0.2738